Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PARP7 inhibitor
- Development stage
- Preclinical
- Lead developer
- Angel Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PARP7 inhibitor is a small molecule therapeutic being developed by Angel Pharmaceuticals for the treatment of various cancers. PARP7, also known as TCDD-inducible poly [ADP-ribose] polymerase (TIPARP), is a mono-ADP-ribosyltransferase that acts as a negative regulator of the type I interferon (IFN) response. By inhibiting PARP7, this drug aims to restore interferon signaling within the tumor microenvironment, thereby enhancing the innate immune system's ability to recognize and attack cancer cells. The program is currently in the preclinical stage of development, and while the specific chemical entity name has not been disclosed, it represents a targeted approach to oncology by modulating the immune response within cancer cells.
- Other names
- PARP7 inhibitorPARP-7 inhibitorPARP 7 inhibitorTIPARP inhibitor
02
Targets
PARP7 (Poly [adp-ribose] polymerase 7)
Beyond the preview
Go deeper on PARP7 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PARP7 inhibitor.